DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Visken (Pindolol) - Side Effects and Adverse Reactions



Most adverse reactions have been mild. The incidences listed in the following table are derived from 12-week comparative double-blind, parallel design trials in hypertensive patients given Visken® (pindolol) as monotherapy, given various active control drugs as monotherapy, or given placebo. Data for Visken® (pindolol) and the positive controls were pooled from several trials because no striking differences were seen in the individual studies, with 1 exception. When considering all adverse reactions reported, the frequency of edema was noticeably higher in positive control trials [16% Visken® (pindolol) vs. 9% positive control] than in placebo controlled trials [6%Visken® (pindolol) vs. 3% placebo]. The table includes adverse reactions either volunteered or elicited, and at least possibly drug related, which were reported in greater than 2% of Visken® (pindolol) patients and other selected important reactions.

Adverse Reactions Which Were Volunteered or Elicited(and at least possibly drug related)
Body System/

Adverse Reactions
Visken ®  









Central Nervous System

   Bizarre or Many Dreams506
Autonomic Nervous System


   Heart Failure<1<10

   Chest Pain313
   Joint Pain744
   Muscle Cramps310
   Muscle Pain1098

   Abdominal Discomfort445


*Active Controls: Patients received either propranolol, α-methyldopa or a diuretic (hydrochlorothiazide or chlorthalidone).

The following selected (potentially important) adverse reactions were seen in 2% or fewer patients and their relationship to Visken® (pindolol) is uncertain. CENTRAL NERVOUS SYSTEM: anxiety, lethargy; AUTONOMIC NERVOUS SYSTEM: visual disturbances, hyperhidrosis; CARDIOVASCULAR: bradycardia, claudication, cold extremities, heart block, hypotension, syncope, tachycardia, weight gain; GASTROINTESTINAL: diarrhea, vomiting; RESPIRATORY: wheezing; UROGENITAL: impotence, pollakiuria; MISCELLANEOUS: eye discomfort or burning eyes.


In addition, other adverse effects not aforementioned have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of Visken® (pindolol).

Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.

Cardiovascular: Intensification of AV block. (See CONTRAINDICATIONS)

Allergic: Erythematous rash; fever combined with aching and sore throat; laryngospasm; respiratory distress.

Hematologic: Agranulocytosis; thrombocytopenic and nonthrombocytopenic purpura.

Gastrointestinal: Mesenteric arterial thrombosis; ischemic colitis.

Miscellaneous: Reversible alopecia; Peyronie’s disease.

The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with Visken® (pindolol) during investigational use and extensive foreign experience amounting to over 4 million patient-years.


Below is a sample of reports where side effects / adverse reactions may be related to Visken. The information is not vetted and should not be considered as verified clinical evidence.

Possible Visken side effects / adverse reactions in 48 year old female

Reported by a consumer/non-health professional from Brazil on 2011-12-09

Patient: 48 year old female

Reactions: Obsessive-Compulsive Disorder, Blood Cortisol Decreased, Panic Disorder, Weight Increased, Anxiety, Bipolar I Disorder, Blood Cholesterol Increased, Hypothyroidism, Blood Corticotrophin Decreased, Hypertension, Decreased Appetite

Suspect drug(s):
    Dosage: 25 mg, unk
    Administration route: Oral

    Dosage: unk ukn, daily

Levothyroxine Sodium
    Dosage: unk ukn, daily

    Dosage: unk ukn, unk

    Dosage: unk ukn, unk

See index of all Visken side effect reports >>

Drug label data at the top of this Page last updated: 2006-10-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017